Global Adrenocortical Carcinoma Drugs Market 2019-2023

The global adrenocortical carcinoma drugs market size will grow by USD 259 million during 2019-2023. This market report provides a detailed analysis of the market by type (chemotherapy and targeted therapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.

Some of the key findings from our adrenocortical carcinoma drugs market forecast report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global Adrenocortical Carcinoma Drugs Industry Overview

The adrenocortical carcinoma drugs market has recorded the development of several advanced imaging techniques, which are non-invasive and exhibit enhanced diagnostic accuracy in the detection of adrenal lesions. For instance, unenhanced computed tomography adrenal densitometry is used to differentiate adrenal adenomas from malignant lesions based on the presence of intracellular lipids. A combination of positron emission tomography/computed tomography is also gaining popularity among end-users for the identification of malignant and benign lesions. Similarly, multiphase computed tomography technique is being used to calculate absolute and relative percentage washout, and thereby, differentiate between benign and malignant lesions. Such advances in imaging techniques for adrenal tumors are identified as one of the critical adrenocortical carcinoma drugs market trends responsible for the growth of the market.

Chemotherapeutics such as mitotane, paclitaxel, 5-fluorouracil, and vincristine are used to treat adrenocortical carcinoma. Mitotane is also used in combination with cisplatin, doxorubicin, and etoposide, to treat adrenocortical carcinoma. However, chemotherapeutics and combination therapy are associated with various side-effects, including nausea and vomiting, peripheral neuropathy, seizures, anemia, and risk of infections. Moreover, chemotherapeutics treatment for adrenocortical carcinoma has low survival rates. These factors have driven researchers to develop novel therapies, which have minimum side-effects and are highly efficacious in the treatment of adrenocortical carcinoma. Hence, the development, approval, and advantages of novel drugs over chemotherapeutics will drive the growth of the adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period.

Top Adrenocortical Carcinoma Drugs Companies Covered in this Market Research Report

The global adrenocortical carcinoma drugs market is concentrated. To help clients improve their market positions, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this adrenocortical carcinoma drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.

The report offers a detailed analysis of several leading adrenocortical carcinoma drugs manufacturers, including:

• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• Laboratoire HRA Pharma SAS
• Progenics Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

Adrenocortical Carcinoma Drugs Market Segmentation Based on Type

• Chemotherapy
• Targeted therapy

The chemotherapy segment will account for the highest adrenocortical carcinoma drugs market share. The rising focus on the development of combination therapies to treat adrenocortical carcinoma will fuel the growth of the market segment over the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the adrenocortical carcinoma drugs market size.

Adrenocortical Carcinoma Drugs Market Segmentation Based on Geographic Region

• Asia
• Europe
• North America
• ROW

With a complete study of the growth opportunities for the companies, it has been identified that North America will account for the highest share of the adrenocortical carcinoma drugs market throughout the forecast period. Factors such as the rising incidence of genetic syndromes, strong presence of vendors, and increasing R&D of drugs to treat adrenocortical carcinoma are responsible for adrenocortical carcinoma drugs market growth in this region.

Key Highlights of the Global Adrenocortical Carcinoma Drugs Market for the Forecast Years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the adrenocortical carcinoma drugs market during the next five years
• Precise estimation of the global adrenocortical carcinoma drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the adrenocortical carcinoma drugs industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of adrenocortical carcinoma drugs companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch